SOURCE: iSonea Limited

iSonea Limited

October 30, 2013 07:30 ET

iSonea Signs Agreement With P&G's TREMOR™ to Promote AirSonea™ to Women

Agreement With TREMOR Provides Access to Women With Asthma; Rigorously Validated Vocalpoint Word-of-Mouth Network Touches a Wide Audience; Network Will Be Instrumental in 2014 US Launch of AirSonea Wheeze Monitor for Asthma

SEVERNA PARK, MD--(Marketwired - October 30, 2013) - Medical technology company iSonea Limited (ASX: ISN) has signed an agreement with TREMOR, a division of global consumer brand leader Procter & Gamble (P&G), aiming to promote AirSonea to women with asthma and mothers of children with asthma.

TREMOR employs state-of-the-art research capabilities and proven community-based social marketing strategies to engage volunteer advocates and create positive word-of-mouth for select brands of interest to their consumer social network.

iSonea CEO Michael Thomas said that working with TREMOR to create awareness and experience with AirSonea among women will play a significant role in the 2014 US launch of the wheeze monitoring device, once FDA regulatory clearance is achieved.

"This presents a tremendous opportunity to develop positive word-of-mouth advocacy among women with asthma and mothers of children with asthma. For a small company like iSonea, this level of access to key consumer audiences is both significant and efficient."

"We are excited to harness their awareness and advocacy programs to help educate people on the need for better asthma monitoring and the ways in which AirSonea addresses that need through rapid detection and measurement of wheeze."

This initiative will begin with extensive customer research conducted within the P&G Vocalpoint community, to determine the most effective messaging for stimulating awareness and interest in the asthma monitoring system. The campaign will launch in 2014 once AirSonea receives FDA 510(k) clearance to market in the US.TREMOR™ is the word of mouth marketing organization developed by Procter & Gamble that combines P&G's wide-ranging marketing expertise with key learnings from cognitive science. TREMOR is a leader in applying these learnings to the idea of consumer advocacy as the driving force behind effective, measurable word-of-mouth marketing campaigns

About iSonea Limited

iSonea Limited (ASX: ISN) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea's proprietary Acoustic Respiratory Monitoring™ (ARM) technology with its AsthmaSense™ mobile applications, iSonea is turning smart phones into personal monitoring devices -- enabling anyone, anywhere, at any time to monitor breathing symptoms associated with asthma. iSonea's ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE.

For more information, please visit www.iSoneaMed.com and www.AsthmaSense.com.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on iSonea's current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

The following files are available for download:

Contact Information